First-Line Sunitinib vs Pazopanib in Metastatic Renal Cell Carcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
First-Line Sunitinib Versus Pazopanib in Metastatic Renal Cell Carcinoma: Results From the International Metastatic Renal Cell Carcinoma Database Consortium
Eur. J. Cancer 2016 Sep 01;65(xx)102-108, JM Ruiz-Morales, M Swierkowski, JC Wells, AP Fraccon, F Pasini, F Donskov, GA Bjarnason, JL Lee, HW Sim, A Sliwczynsk, A Ptak-Chmielewska, Z Teter, B Beuselinck, LA Wood, T Yuasa, C Pezaro, BI Rini, C Szczylik, TK Choueiri, DY HengFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.